| Literature DB >> 26479518 |
L V Kalman1, Jag Agúndez2, M Lindqvist Appell3, J L Black4, G C Bell5, S Boukouvala6, C Bruckner7, E Bruford8, K Caudle9, S A Coulthard10, A K Daly10, Al Del Tredici11, J T den Dunnen12, K Drozda13, R E Everts14, D Flockhart15, R R Freimuth4, A Gaedigk16, H Hachad17, T Hartshorne18, M Ingelman-Sundberg19, T E Klein20, V M Lauschke19, D R Maglott21, H L McLeod5, G A McMillin22, U A Meyer23, D J Müller24, D A Nickerson25, W S Oetting26, M Pacanowski13, V M Pratt15, M V Relling9, A Roberts27, W S Rubinstein21, K Sangkuhl20, M Schwab28, S A Scott29, S C Sim19, R K Thirumaran30, L H Toji31, R F Tyndale32, Rhn van Schaik33, M Whirl-Carrillo20, Ktj Yeo34, U M Zanger28.
Abstract
This article provides nomenclature recommendations developed by an international workgroup to increase transparency and standardization of pharmacogenetic (PGx) result reporting. Presently, sequence variants identified by PGx tests are described using different nomenclature systems. In addition, PGx analysis may detect different sets of variants for each gene, which can affect interpretation of results. This practice has caused confusion and may thereby impede the adoption of clinical PGx testing. Standardization is critical to move PGx forward. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.Entities:
Mesh：
Year: 2015 PMID： 26479518 PMCID： PMC4724253 DOI： 10.1002/cpt.280
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875